• Aldeyra Therapeutics on patent portfolio management and IP counseling to support their ocular drug candidate for the treatment of a variety of ocular disorders including macular degeneration, allergic conjunctivitis, uveitis, dry eye, and Sjogren-Larsson Syndrome. In addition to securing global patent protection for their drug candidate, clinical indications, and formulations, we guide the company through intellectual property investigations conducted by investors and potential partners.
    • Ferring Pharmaceuticals in connection with its acquisition of Rebiotix Inc. (RBX), a late-stage clinical microbiome company that has pioneered the application of microbiome therapy. Assessment of the strength of the Rebiotix patent portfolio was a critical aspect of the deal as the IP was the major asset acquired. The acquisition expands Ferring’s reach into the microbiome space.
    • Kymera Therapeutics in its up-to-US$2 billion multi-program, strategic collaboration with French pharmaceutical company Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. Dechert negotiated and drafted the very complex IP terms of the deal, including patent strategy and due diligence.
    • Merck KGaA in its due diligence and negotiation of patent terms for a licensing agreement with Vertex Pharmaceuticals for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer. As part of the agreement, Merck KGaA will license two clinical-stage programs targeting DNA damage and repair, along with two additional novel pre-clinical programs. Vertex will receive an upfront payment of US$230 million, in addition to royalties on future net sales. Merck KGaA will assume full responsibility for the development and commercialization of all the programs.
    • Nimbus Apollo in developing and implementing a drug discovery patent strategy and, later, a focused patent strategy protecting the lead drug candidate in human clinical trials. Subsequently, the company was acquired by Gilead Sciences for US$1.2 billion.
    • Pfizer in securing patent protection for Ibrance® (palbociclib), an FDA-approved oral drug for first line treatment of HR-positive/HER2-negative breast cancer, the most common type of breast cancer (70% of all cases). This representation also includes management of Pfizer’s patent term extension (PTE) strategy for Ibrance® and involves extensive dialog and negotiation with the U.S. Patent and Trademark Office.
    • PureTech Health, a clinical-stage biopharmaceutical company, on IP-related aspects of its US$1 billion deal with Roche to advance its milk-derived exosome platform technology for the oral administration of antisense oligonucleotide platform.
    • Royalty Pharma, which sparks sector innovation by co-funding clinical trials and new product launches in exchange for future royalties and acquiring existing royalties from innovators, as lead counsel on the IP issues underpinning multiple transactions. Since late-2019, these have totaled more than US$2 billion.
  • Dechert’s patent counseling and prosecution team is actively engaged in virtually all sectors of the life sciences industry, which is why many high-profile companies entrust us with their most critical patent development, protection and enforcement issues. Described as “A key player in the firm's international life sciences practice and well versed in multi-jurisdictional matters. ‘Highly creative team, especially in the small molecule and formulation areas.’” by The Legal 500 US: Nationwide: Patent Prosecution, 2020. Recommended for patent portfolio management by Chambers USA: Nationwide: Life Sciences, 2020, our team is also consistently recognized as having the World’s Leading Patent Professionals by Intellectual Asset Management’s IAM Patent 1000.

    Notable Dechert clients include:

    • Abbott Biotherapeutics (Facet Biotech)
    • AbbVie Biotherapeutics
    • Aldeyra Therapeutics
    • Arrakis Therapeutics
    • AstraZeneca (Omthera Pharmaceuticals)
    • Atlas Venture
    • Biogen
    • Bristol-Myers Squib (Padlock Therapeutics)
    • Bicycle Therapeutics
    • Celgene Corporation
    • Daiichi Sankyo
    • Ferring Pharmaceuticals
    • Ikena Oncology
    • Kymera Therapeutics
    • Merck & Co. (Cubist Pharmaceuticals)
    • Merck KGaA
    • Merz Pharmaceuticals
    • Navitor Pharmaceuticals
    • Nimbus Therapeutics
    • Norgine Pharmaceuticals
    • Onconova Therapeutics
    • Pfizer
    • Purdue Pharma
    • PureTech Health
    • resTORbio
    • Royalty Pharma
    • Vertex Pharmaceuticals
    • X4 Pharmaceuticals